Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 13

63P - Intrahepatic cholangiocarcinoma (iCCA) genomic findings with high versus low tumor mutational burdens


10 Sep 2022


Poster session 13


Cancer Biology;  Pathology/Molecular Biology;  Translational Research;  Molecular Oncology

Tumour Site

Hepatobiliary Cancers


Tin-Yun Tang


Annals of Oncology (2022) 33 (suppl_7): S19-S26. 10.1016/annonc/annonc1036


T. Tang1, J.S. Ross2, J. Rodon3, M. Javle4

Author affiliations

  • 1 Division Of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 77030 - Houston/US
  • 2 Pathology Department, Foundation Medicine, Inc, 02141 - Cambridge/US
  • 3 Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 77030 - Houston/US
  • 4 Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 77030-4095 - Houston/US

Abstract 63P


Less than 5% of iCCA are tumor mutational burden-high (TMB-H), defined as ≥10 mut/Mb. The TMB-low (TMB-L), defined as ≤10 mut/Mb, have not been contrasted. Ongoing interest in the development of combination immunotherapy strategies make characterizing the genomic landscape of TMB-H iCCAs clinically relevant.


3,317 cases of iCCA underwent comprehensive genomic profiling with the FoundationOne CDx assay. Prevalence of different genomic alterations in cases with TMB-H were compared against TMB-L using Fischer’s exact test.


127 (3.9%) of 3,190 cases were TMB-H and of these cases 32.6% were TMB ≥ 20 mut/Mb. Compared to TMB-L cases, microsatellite instability (MSI) was higher in TMB-H (35.5% v 0.1%, p<.0001), as was high (≥50%) PD-L1 IHC staining (8.9% v 2.9%, p=0.47) and mutations in potential immunotherapy biomarkers PBRM1 (17.5% v 10.7%, p=.028) and STK11 (10.3% v 2.8%, p=.0001). TMB-H cases have lower frequencies of previously identified iCCA drivers such as FGFR2 fusions (0.8% v 8.2%, p=.0006), IDH1 mutations (1.6% v 14.0%, p<.0001) and IDH2 mutations (0% v 4.3%, p=.01). ERBB2 non-amplification structural variants are also increased (5.6% v 1.1%, p=.0009) in TMB-H. Mutations in genes with roles in genomic stability were increased with TP53 (61.9% v 34.1%, p<.0001) and ARID1A (38.9% v 17.8%, p<.0001). TMB-H cases had higher mutations in BRCA2 (7.9% v 2.2%, p=.0008) and ATM (7.9% v 3.1%, p=.008), but not BRCA1 (2.4% v 0.8%, NS). In contrast, TMB-L cases have higher incidences of CDKN2B (22.3% v 9.5%, p=.0003) and MTAP mutations (15.4% v 7.1%, p=.008).


TMB-H is nearly mutually exclusive with previously identified iCCA drivers such as IDH1, IDH2 and FGFR2 fusions. Additionally, TMB-H cases have a nearly two-fold increase in mutations in TP53 and ARID1A. Mutations in homologous recombination genes such as BRCA2 and ATM are enriched, but their overall incidence is low. Finally, TMB-H cases are enriched in multiple independent biomarkers of response to immunotherapy such as MSI, PD-L1, evolving ones such as PBRM1 and STK11 and depleted in resistance biomarkers such as MTAP. These findings support the clinical development of immunotherapy approaches for the treatment of TMB-H iCCA.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Foundation Medicine.


J.S. Ross: Financial Interests, Personal, Full or part-time Employment, Medical Director: Foundation Medicine; Financial Interests, Personal, Stocks/Shares: Roche Holdings, Tango Therapeutics, Celsius Therapeutics. J. Rodon: Financial Interests, Personal, Advisory Board: Peptomyc, Kelun Pharmaceuticals/Klus Pharma, Ellipses Pharma, Molecular Partners, IONCTURA SA; Financial Interests, Institutional, Other, Clinical Research: Bayer, Novartis, Spectrum Pharmaceuticals, Symphogen, BioAlta, Pfizer, GenMab, CytomX, Kelun-Biotech, Takeda-Millenium, GlaxoSmithKline; Financial Interests, Institutional, Other, Research Funding: Blueprint Medicines, Black Diamond, Merck Sharp & Dohme; Financial Interests, Institutional, Research Grant, Research Funding/Clinical Research: Hummingbird, Yingli; Financial Interests, Institutional, Research Grant, Research Funding: Vall d'Hebron Institute of Oncology/Cancer Core Europe; Financial Interests, Institutional, Research Grant, Clinical Research: Bicycle Therapeutics, Taiho, Roche Pharmaceuticals, Merus, Curis, AadiBioscience, Nuvation, ForeBio, BioMed Valley Discoveries, Loxo Oncology, Hutchinson MediPharma, Cellestia, Deciphera, Ideaya, Amgen, Tango Therapeutics, Mirati, Linnaeus Therapeutics; Other, , Other, Other: VHIO/Ministero De Empleo Y Seguridad Social, Chinese University of Hong Kong, Boxer Capital, LLC, Tang Advisors, LLC; Other, Other, Travel Reimbursement: European Society for Medical Oncology. M. Javle: Financial Interests, Personal, Advisory Board: QED, Taiho, Merck, Transthera, Incyte, Servier, AstraZeneca; Financial Interests, Personal, Invited Speaker: Oncosil, INCYTE; Non-Financial Interests, Principal Investigator: qed, Basilea. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.